CBIO Insider Trading Activity and SEC Form 4 Filings
CBIO insider trading summary
Over the past 12 months, insiders at Crescent Biopharma, Inc. (CBIO) reported 16 sales worth $1.5M by 7 insiders and 8 open-market purchases worth $122.5M by 4 insiders on SEC Form 4. Net insider buying was $120.9M.
Latest CBIO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 18, 2026 | Joshua T Brumm | Chief Executive Officer | Sell | $131K (7,837 @ $16.71) |
| Sep 18, 2026 | Jonathan McNeill | President and COO | Sell | $64K (3,839 @ $16.71) |
| Sep 16, 2026 | Jan Pinkas | Chief Scientific Officer | Sell | $12K (658 @ $17.90) |
| Sep 16, 2026 | Richard William Scalzo | Chief Financial Officer | Sell | $10K (568 @ $17.90) |
| Sep 16, 2026 | Barbara Harlin Bispham | See Remarks | Sell | $11K (620 @ $17.90) |
| Sep 16, 2026 | Joshua T Brumm | Chief Executive Officer | Sell | $29K (1,610 @ $17.90) |
| Sep 16, 2026 | Ryan Lynch | See Remarks | Sell | $4K (240 @ $17.90) |
| Sep 16, 2026 | Jonathan McNeill | President and COO | Sell | $13K (731 @ $17.90) |
| Sep 16, 2026 | Ellie Eunkyung Im | Chief Medical Officer | Sell | $11K (623 @ $17.90) |
| Jul 16, 2026 | Peter Evan Harwin | Director | Buy | $12.4M (853,450 @ $14.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.